Trial Profile
A Prospective, Multicenter, Randomized Controlled Clinical Trial of Bevacizumab in the Treatment of Malignant Pleural Effusions of Non-squamous Non-small Cell Lung Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Aug 2022
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Malignant pleural effusion; Non-small cell lung cancer
- Focus Therapeutic Use
- 24 Oct 2016 New trial record